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ObjectiveaaLamotrigine is a widely used medication for psychiatric disorders and epilepsy, but the adverse effects of this drug in ado-
lescent Korean patients have not yet been investigated. In the present study, we sought to compare the incidence and impact of lamotrig-
ine-induced skin rashes and different pattern of adverse events in psychiatric and nonpsychiatric adolescent patients.
MethodsaaUsing a retrospective cohort design, all of the charts were reviewed for adolescents (13 to 20 years old), treated with la-
motrigine during the previous 2 years in the Child and Adolescent Psychiatric Clinic and Pediatric Neurologic Clinic of the Ulsan Uni-
versity Hospital in South Korea.
ResultsaaOf the 102 subjects, 23 patients developed a skin rash. All of these rashes were observed within 7 weeks of the initiation of the 
lamotrigine therapy. Only one subject developed a serious rash, which was diagnosed as Stevens-Johnson syndrome. Although the psy-
chiatric subjects were administered statistically lower doses of lamotrigine during weeks 1 through 5 and at week 12, the likelihood of 
developing a rash was not significantly different between the psychiatric and nonpsychiatric patients. 
ConclusionaaCareful dose escalation and close observation of side effects for the first 7 weeks of treatment is important. The present 
study reveals the tolerability of lamotrigine in an adolescent population, although a double-blind, controlled trial is needed to confirm 
these findings.  Psychiatry Investig 2012;9:174-179
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INTRODUCTION
Lamotrigine (LTG) is an anticonvulsant medication that 
has been used widely for adult and pediatric seizure disorders. 
LTG is approved by the U.S. Food and Drug Administration 
(FDA) for the maintenance treatment of bipolar disorder in 
adults and as an adjunctive therapy in epilepsy.
1 This drug has 
also been used in youths with psychiatric disorders as a mood 
stabilizer.
2 The common side effects of LTG include dizziness, 
ataxia, headache, tremor, blurred vision, and diplopia.
3 Ap-
proximately 8% of patients who are administered LTG devel-
op a benign maculopapular rash during the first 4 months of 
treatment.
4 In adults, the incidence of serious rashes was 0.08% 
when LTG was used as the initial monotherapy and was 0.13% 
when this drug was used as an adjunctive therapy.
4 Lamotrig-
ine carries a U.S. Food and Drug Administration-mandated 
black box warning concerning the increased risk of rashes in 
children under the age of 16 years.
1 Skin rashes are a major 
cause of treatment discontinuation for this medication. These 
skin reactions range, with increasing severity, from common 
and mild maculopapular rashes to Stevens-Johnson syn-
drome (SJS) and toxic epidermal necrolysis (TEN). Although 
these reactions are rare, they are more common in children 
than in adults, and it is difficult to predict whether a rash will 
progress to SJS or TEN.
3-5 Serious reactions are rare but may 
be life-threatening.
6
The pathogenesis of skin reactions appears to be multifac-
torial and has, in many cases, been explained using the hapten 
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hypothesis of drug hypersensitivity, which implies that meta-
bolic and immunological mechanisms are involved. The im-
mune response is initiated by reactive metabolites that are 
combined with self proteins. An imbalance between the met-
abolic bioactivation and detoxification of the drug may lead 
to an accumulation of reactive metabolites, which may bind 
irreversibly to endogenous proteins.
7 T-cell lymphocyte clon-
es may react to these drug-modified proteins, or to the paren-
tal drug itself, and cause delayed immune responses in the 
skin, whereas immediate IgE responses are responsible for ur-
ticaria, angioedema, and anaphylaxis.
8 Among the traditional 
antiepileptic drugs, the aromatic compounds phenytoin and 
carbamazepine have been associated with relatively high inci-
dences of cutaneous reactions in up to 10% of patients.
9-11 La-
motrigine has also been shown to frequently cause this type 
of skin reaction.
12,13
Studies using LTG for epilepsy indicate that the risk factors 
that are associated with serious rashes and lamotrigine treat-
ment include a young age, a large starting dose, a rapid dose 
escalation, and the combination of LTG and valproate.
3-5,12,14 
In previous studies, females were found to be at a higher risk 
of developing an LTG-induced rash than males.
12,15 Clinicians 
now initiate LTG treatment using a slow titration schedule. 
These dosing changes have reduced the incidence of serious 
rashes in pediatric LTG use to approximately 1%.
16 However, 
compared with the pediatric use of LTG, the use of this drug 
in children and adolescent psychiatric patients is much more 
limited, even though this medication exhibits a possible effi-
cacy for mood symptoms.
2
In the present study, we aimed to study the safety and toler-
ability of lamotrigine in adolescents with psychiatric disorders 
who were experiencing a depressive symptoms, with a focus 
on the risk factors that were associated with rash develop-
ment. We compared the incidence and impact of lamotrigine-
induced skin rashes and pattern of adverse events in our sam-
ple with pediatric seizure disorder patients.
METHODS
This retrospective cohort study enrolled consecutive 106 
adolescents (13 to 20 years old) who had been first treated 
with lamotrigine during the previous 2 years in the Child and 
Adolescent Psychiatric Clinic and Pediatric Neurologic Clinic 
of the Ulsan University Hospital in South Korea. Inclusion 
criteria were patients being prescribed Lamotrigine for the 
first time during the study period. Among them, four patients 
with seizure disorder having concurrent psychiatric disorders 
were excluded. The study protocol was approved by the Insti-
tutional Review Board of the Ulsan University Hospital. 
The data were collected by the investigators, M.D. H. J. Tak, 
using chart reviews, which gathered the following data: age, 
sex, DSM-IV diagnosis, ICD-10 diagnosis, and concurrent 
medications (i.e., antipsychotics, mood stabilizers, antidepres-
sants, and stimulants). The presence of any adverse effects was 
also noted.
Diagnoses for the psychiatric patients were made by a child 
psychiatrist, S. Y. Bhang., using clinical interviews that were 
based on the DSM-IV TR criteria and on all of the available 
collateral information. For the pediatric patients, the seizure 
disorders were diagnosed by pediatric neurologist, G. Y. Lee, 
using the ICD-10 criteria. 
Any comment of side effect in the medical record was col-
lected. The expression such as “rash”, “eruptions”, and “urti-
caria” was considered as having rash, but “Pruritis” or “itch-
ing” sensation was not included. In this study, we defined 
“serious rash” as a condition that is life threatening, requiring 
hospitalization, Stevens Johnson syndrome or erytherma 
multiforme.
Statistical analyses
The continuous measures were compared using an inde-
pendent t-test to determine whether there were significant 
differences in the demographic and dosage data between the 
patients who developed a rash and those who did not. An in-
dependent t-test was also used to compare the data of the 
psychiatric and nonpsychiatric patients. Unless otherwise 
specified, the data are presented as the means±standard de-
viations. 
A chi-square test was used to analyze the frequency of the 
other adverse events. To define the factors that affected the 
onset of a rash, we also performed chi-square tests to evaluate 
valproate co-administration and the LTG dose across the 
weeks of treatment. The data were analyzed using SPSS ver-
sion 17.0.
RESULTS
Of the 102 subjects, 65 (64%) were psychiatric patients, and 
37 (36%) were pediatric patients. Among these 102 patients, 
43 (42%) were males, and 59 (58%) were females. The average 
age of the subjects was 17.18 (range=13 to 20, SD=1.864) 
years (Table 1). The primary DSM-IV diagnoses for the psy-
chiatric participants included bipolar disorder (n=39), major 
depressive disorder (n=12), schizophrenia and schizoaffective 
disorder (n=13), and an eating disorder (n=1). The remaining 
37 pediatric patients were diagnosed with seizure disorders 
(Table 1).
Twenty-three patients (22% of all of the participants) devel-
oped a rash during the course of the study period (Table 2). 
The incidence of a rash was not different between the males 176  Psychiatry Investig 2012;9:174-179
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(n=9, 21% of males) and females (n=14, 24% of females) (p= 
0.738).
To evaluate the different rates of rash development between 
the psychiatric and nonpsychiatric patients’ use of LTG, we 
conducted chi-square tests but found no statistically signifi-
cant differences between the groups (p=0.248) (Table 2).
Seventeen psychiatric patients (73.9% of the total rash 
group) and 6 pediatric patients (26.1% of the total rash group) 
developed a rash. The psychiatric subjects were prescribed a 
statistically significant lower dose of LTG in weeks 1 through 
5 and in week 12: 19.80 mg vs. 46.08 mg for the 1
st week (p= 
0.002), 29.56 mg vs. 54.30 mg for the 2
nd week (p=0.007), 
43.75 mg vs. 84.04 mg for the 3
rd week (p=0.000), 50.26 mg vs. 
85.00 mg for the 4
th week (p=0.019), 55.44 mg vs. 119.74 mg 
for the 5
th week (p<0.001), and 88.63 mg vs. 174.42 mg for the 
12
th week (p=0.015).
To evaluate the effects of concurrent valproate and LTG use 
on rash development, we performed a chi-square test. There 
was no difference in the rate of rash development between the 
group that used valproate and the group that did not (p= 
Table 1. Demographic and clinical characteristics of subject
Psychiatric group (N=65) Pediatric group (N=37) Significance
Age, year (mean±SD) 17.52±1.63 16.57±2.10
Age, year-range 13-20 13-20
Age-male (mean±SD) 17.96±1.45 17.12±1.81
Age-female (mean±SD) 17.12±1.81 16.33±2.20
Sex
p=0.156
Male/Female 24/41 19/18
Primary diagnosis
Epilepsy 0             37 (100%) p<0.001*
Bipolar disorder                   39 (60.00%) 0 p<0.001*
Major depressive disorder                   12 (18.46%) 0 p<0.001*
Schizophrenia, schizoaffective disorder                   13 (20.00%) 0 p<0.001*
Eating disorder                     1 (1.54%) 0 p<0.001*
Lamotrigine dose
Initial dose (mean±SD) (range)   19.80±7.29 (12.5-50)  46.08±48.09 (12.5-300) p<0.001
Peak dose (mean±SD) (range) 85.76±63.19 (12.5-200)            167.90±98.88 (12.5-350) p=0.001
Rash dose (mean±SD) (range) 33.38±24.66 (12.5-100)              85.71±53.72 (50-200) p=0.118
*Fisher’s exact test
Table 2. Common adverse events during treatment between psychiatric and pediatric group, and rash and non-rash group
N (%)
Psychiatric 
group
Pediatric
group
Significance Rash group Non-rash group Significance
Rash 23 (22.5%) 17 (26.2%) 6 (16.2%) 0.248 23 (22.5%)   0 (0%)
Weight gain   9 (8.8%)   6 (9.2%) 3 (8.1%) 1*   1 (4.35%)   8 (10.12%) 0.68*
Weight loss   5 (4.9%)   2 (3.1%) 3 (8.1%) 0.350*   1 (4.35%)   4 (5.06%) 1*
Sedation 17 (16.7%) 12 (18.5%) 5 (13.5%) 0.519   1 (4.35%) 16 (20.24%) 0.11*
Tremor   5 (4.9%)   4 (6.2%) 1 (2.7%) 0.651*   2 (8.70%)   3 (3.79%) 0.315*
Pruritus   9 (8.8%)   5 (7.7%) 4 (10.8%)  0.072*   5 (21.73%)   4 (5.06%) 0.026*
GI discomfort 11 (10.8%) 10 (15.4%) 1 (2.7%) 0.053*   2 (8.70%)   9 (11.39%) 1*
Headache    8 (7.8%)   3 (4.6%) 5 (13.5%) 0.135*   2 (8.70%)   6 (7.59%) 1*
Dizziness   3 (2.9%)   1 (1.5%) 2 (5.4%) 0.297* 0   3 (3.79%) 1*
Extrapyramidal  
  symptom
14 (13.7%) 13 (20.0%) 1 (2.7%) 0.016*   1 (4.35%) 13 (16.45%) 0.182*
Hair loss   4 (3.9%)   1 (1.5%) 3 (8.1%) 0.134* 0   4 (5.06%) 0.572*
Irritability    8 (7.8%)   4 (6.2%) 4 (10.8%) 0.456*   2 (8.70%)   6 (7.59%) 1*
Mood elation   4 (3.9%)   4 (6.2%) 0 (0%) 0.294*   2 (8.70%)   2 (2.53%) 0.218*
*Fisher’s exact test. GI: gastrointestinalHJ Tak et al. 
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0.304). Fourteen (21.5%) of psychiatric patients and 9 (24.3%) 
of seizure disorder patients had been taking valproate as a 
concurrent medication. The difference of the proportion was 
not statistically significant (Table 4).
In terms of the dosages of LTG, the mean initial dose of 
LTG in the valproate co-medication group (21.41±14.90 mg) 
was lower than that in the non-valproate group (31.64±35.11 
mg), but this difference was not statistically significant. How-
ever, LTG dosages in the 2nd through the 5th weeks of treat-
ment in the valproate group were statistically significantly 
lower than those in the non-valproate group: 23.52 mg vs. 
42.85 mg for the 2
nd week (p=0.023), 40.37 mg vs. 64.28 mg 
for the 3
rd week (p=0.006), 48.42 mg vs. 69.05 mg for the 4
th 
week (p=0.026), and 57.65 mg vs. 90.62 mg for the 5
th week 
(p=0.006).
All of the rashes that were observed occurred within 7 
weeks (n=23, 100%) of the treatment initiation in our sub-
jects. The mean time interval to the rash onset from the start-
ing time of the LTG treatment was 2.7 weeks (range=1 to 7 
weeks, SD=1.428). The LTG dose in week 3 (mean 39.84± 
21.02 mg vs. 63.10±50.73 mg) and the mean peak dose 
(71.19±73.12 mg vs. 128.48±87.01 mg) were found to be sta-
tistically significantly lower in the group that developed a rash 
than in the group that did not develop a rash (Table 3). The 
incidence of pruritus was significantly different between the 
rash group (n=5, 21.7%) and the non-rash group (n=4, 5.1%). 
The patients with pruritus were likely to develop a rash. Be-
fore and after the development of the rashes, 5 patients expe-
rienced pruritic sensations (p=0.026). In addition, 4 patients 
suffered from pruritus without a rash during LTG treatment. 
However, the incidences of the other side effects of LTG were 
not different between the groups (Table 2). A 15-year-old male 
with a seizure disorder (n=1, 0.98% of all subjects) developed 
a serious rash, which was diagnosed as Stevens-Johnson syn-
drome and required hospitalization for 2 weeks. He was tak-
ing valproate 750 mg, and lamotrigine was added to his treat-
ment regimen to further control his seizures. The rash app-
eared during the 3
rd week of the lamotrigine treatment at a 
dose of 100 mg. After the hospitalization, the rash remitted 
completely with no long-term complications. Two subjects be-
gan steroid treatment for 2 weeks and another subject began 
antihistamine medication for days after development of rash.
At week-12, the number of subjects of non-rash group who 
continued the lamotrigine medication was 55 (69% of base-
line) (Table 3). Two main reasons why non-rash group dis-
continued the medication at week-12 were lack of efficacy 
and poor compliance.
Twenty one patients (91.3%) discontinued the use of la-
motrigine after the onset of a rash. Two (8.7%) patients con-
tinued the medication. Among the discontinuation patients, 
18 (78.2%) subjects stopped the lamotrigine immediately af-
ter the onset of rash, 3 (13%) patients discontinued the drug 
gradually after trying to manage the rash through dose reduc-
tion. Two patients rechallenged LTG after discontinuing the 
use of the medication for 2 months for one patient, and 2.5 
years for the other. These two patients had no reappearance of 
Table 3. Differences of dose escalation patterns according to the psychiatric/non psychiatric group and rash/non-rash group
Psychiatric group Pediatric group Significance Rash group Non-rash group Significance
Baseline 19.81±7.29 (N=65) 46.08±48.09 (N=37) 0.002 21.19±10.94 (N=23) 31.70±35.50 (N=79) 0.166
Week 2 29.56±16.85 (N=63) 54.30±50.90 (N=36) 0.007 31.81±21.03 (N=22) 40.48±38.33 (N=77) 0.312
Week 3 43.75±32.77 (N=56) 84.04±57.28 (N=34) <0.001 39.84±21.02 (N=16) 63.10±50.73 (N=74) 0.005
Week 4 50.26±34.93 (N=48) 85.00±56.94 (N=32) 0.019 54.80±39.04 (N=13) 65.97±49.44 (N=67) 0.445
Week 5 55.45±39.51 (N=39) 119.74±66.60 (N=29) <0.001    63.88±46.53 (N=9) 85.76±63.13 (N=59) 0.323
Week 12 88.64±58.07 (N=33) 174.42±85.02 (N=26) 0.015  93.75±109.21 (N=4) 128.81±81.11 (N=55) 0.417
Peak dose 85.77±63.19 (N=65) 167.91±98.89 (N=37) <0.001 71.19±73.12 (N=23) 128.48±87.01 (N=79) 0.005
Table 4. Differences of concurrent medication between psychiatric and pediatric group
Psychiatric group Pediatric group Significance
Valproate 14 (21.5%)   9 (24.3%)    0.746
Lithium 38 (58.5%) 0 <0.001*
Antipsychotics 57 (87.8%) 0 <0.001*
SSRI   2 (3.1%) 0    0.533*
Methylphenidate   7 (10.8%) 0    0.046*
Levetracetam 0 1 (2.7%)    0.363*
Oxcarbazepine 0   4 (10.8%)    0.016*
Antipsychotics includes zyprexa, risperidone, aripiprazole, amisulpride, ziprasidone, paliperidone and quetiapine. *Fisher’s exact test. SSRI: 
selective serotonin reuptake inhibitor178  Psychiatry Investig 2012;9:174-179
Lamotrigine Induced Skin Rash in Korean Adolescents
rash after restarting the LTG.
Overall, rash was the most common side effect, which was 
followed by sedation (n=17, 16.7%), extrapyramidal symp-
toms (EPS) (n=14, 13.7%), gastrointestinal discomfort (n=11, 
10.8%), weight gain (n=9, 8.8%), and weight loss (n=5, 4.9%) 
(Table 2). The rates of EPS were higher in the psychiatric 
group (n=13, 20%) compared to the nonpsychiatric group 
(n=1, 2.7%) (p=0.016). None of the other side effects, besides 
rash and EPS, exhibited significant differences between the 
psychiatric and nonpsychiatric groups (Table 2). Among the 
14 patients who developed EPS, 13 were taking concurrent 
antipsychotic medications.
DISCUSSION
The present study is the first to compare the side effects of 
LTG in adolescent epilepsy patients and adolescent psychiat-
ric patients. This retrospective cohort study was conducted 
with patients who were aged 13 to 20 and who were newly 
prescribed LTG for the same 2-year period. 
Lamotrigine has therapeutic effects in pediatric patients 
with bipolar disorder. Lamotrigine is an antiglutamatergic 
agent that decreases the activity of glutamate, an excitatory 
neurotransmitter, thus relieving depression while not affect-
ing mania in patients with bipolar disorder.
17 Therefore it is an 
emerging option for treatment of depression in pediatric bi-
polar disorder.
18 A community study that examined the pat-
tern of medication use in children and adolescents who were 
treated for bipolar disorder found that 15% of these patients 
were treated with new generation antiepileptic drugs before 
standard mood stabilizers.
19 Lamotrigine monotherapy has 
been shown to be effective in maintaining depressive symp-
tom control in pediatric bipolar disorder.
2,20,21 As illustrated by 
these studies, LTG appears to be effective in treating depres-
sive symptoms in adolescent psychiatric disorders.
As adjunctive therapy in pediatric patients with epilepsy, 
11.5% of patients aged 2 to 16 years who received LTG dis-
continued treatment because of an adverse reaction.
1 The re-
action that was most commonly associated with treatment 
discontinuation was a rash.
1,20 The incidence of a serious rash 
that was associated with hospitalization and the discontinua-
tion of lamotrigine in the pediatric patients (2 to 16 years of 
age) was 0.8% (16 of 1983).
1 In our study, only one patient 
had a serious rash and required hospitalization, which con-
firms the safety of LTG that has been shown in previous stud-
ies. However, compared with these previous studies, the inci-
dence rate of a benign rash (n=22, 21.56% of all participants) 
in our present study was the highest, despite the slow titration 
of the medication in psychiatric patient group. In previous 
study on Korean adults, they report 12.5% and 12.7% of the 
rash incidence.
22,23 In one study on Chinese adult epileptic pa-
tients prescribed with lamotrigine reported that 4.7% of the 
participants experienced rash.
24 In children with bipolar spec-
trum disorder, 38.4% (n=15/39) of youth developed skin le-
sion and among them, 17.9% (n=7/39) patients developed 
rash.
21 In one study for bipolar manic and hypomanic adoles-
cent patient, 6.4% developed rash.
2
Lamotrigine is metabolized exclusively by glucuronidation, 
and valproate inhibits the glucuronidation of this drug and 
decreases its clearance by approximately 50%.
3 The addition 
of valproate to a patient’s treatment regimen may significantly 
elevate LTG levels and may increase the likelihood of devel-
opment of life-threatening SJS
3 as a result of this drug’s inhibi-
tion of uridine diphosphate glucuronyltransferase.
25 However, 
valproate was not identified as a risk factor in our study, whi-
ch was likely due to careful LTG dosing in accordance with 
current guidelines, especially for the psychiatric patients. 
It is already recognized that drug-induced skin reactions, in 
general, are more frequent in women than in men.
15,26 This 
gender difference has been reported previously for LTG.
12 In 
our study, there were no gender differences in the rash devel-
opment. In a recent study, significant gender difference was 
not reported for LTG rashes.
13
Common side effects of lamotrigine include dizziness, 
ataxia, headache, tremor, blurred vision, and diplopia.
3 In our 
sample, sedation, extrapyramidal symptoms and gastrointes-
tinal symptoms were common side effects; weight gain, wei-
ght loss, tremor, pruritus, headache, dizziness, hair loss, irrita-
bility, and mood elevation were also noted (Table 2). No other 
side effects were found to result in the discontinuation of LTG 
in our study. Except for rash, LTG is generally well tolerated as 
an anticonvulsant and as an antidepressant mood stabilizer.
27
For the nonpsychiatric seizure patients, the pediatrician ti-
trated lamotrigine dose more rapidly than manufacturer’s ad-
vice because of clinical demand for seizure control. In spite of 
this, the incidence of rash between psychiatric and nonpsy-
chiatric patients was not statistically different. This supports 
that lowering starting dosage of lamotrigine can reduce the 
incidence of serious rash but not the overall incidence of la-
motrigine related rash.
12
Compared to previous reports, which did not report the 
existence of EPS, the EPS rate was significantly high for the 
psychiatric patients in the present study. One explanation for 
this relatively high EPS rate is the co-medication of these pa-
tients with antipsychotics (n=13, 92.85% of 14 EPS reporting 
subjects). Another explanation may be that the adolescent 
population often displays a higher level of sensitivity to medi-
cation toxicity than adults.
28 Compared to adults, adolescents 
have a higher risk of dystonic reactions with the use of anti-
psychotic agents.
29,30HJ Tak et al. 
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The major limitation of the present study is that it is based 
on a retrospective analysis. The precious estimates of rash 
rates can be obtained from prospective clinical studies, which 
do allow for a careful follow-up with the patients and do pro-
vide detailed descriptions of all of the emerging adverse ev-
ents. Second, our study sample was derived from one univer-
sity hospital clinic, a factor which may have limited the re-
presentativeness of our data. Multicenter studies are required 
to generalize the findings of a study to heterogeneous patient 
populations with diverse clinical presentations. In addition, 
we did not examine the patients’ histories for prior rashes that 
were developed as a result of previous medications, including 
other antiepileptic drugs. A history of rash from other antiep-
ileptic drugs is a risk factor for developing rash to LTG.
13 
Third, the clinical response of depressive symptoms was not 
evaluated. Other limitations include the small number of pa-
tients in some of the subgroups, and the possible presence of 
a physician bias during the determination of whether or not a 
rash was related to a given medication. Controlled and pro-
spective longitudinal studies that use larger samples of pa-
tients are needed to further investigate the predictors of LTG 
associated rash.
The present study is the first to investigate lamotrigine in 
adolescent psychiatric disorders and in epilepsy in Korea. The 
main aim of the present study was to determine the tolerabili-
ty and safety of LTG in this population. The results of the cur-
rent study support our hypothesis that LTG is tolerable in this 
special population.
2 Despite the many limitations of this ret-
rospective study, our observations show that LTG is tolerable 
and has a relatively low incidence of serious rash.
REFERENCES
1. GlaxoSmithKline. Prescribing Information: Lamictal.[Online]. GlaxoS-
mithKline; 2009.
2. Pavuluri MN, Henry DB, Moss M, Mohammed T, Carbray JA, Sweeney 
JA. Effectiveness of lamotrigine in maintaining symptom control in pe-
diatric bipolar disorder. J Child Adolesc Psychopharmacol 2009;19:75-
82.
3. Martin A, Volkmar FR, Lewis M. Lewis’s Child and Adolescent Psychi-
atry: A Comprehensive Textbook. 4th Edition. Philadelphia: Lippin-
cott Williams & Wilkins; 2007.
4. Sadock BJ, Kaplan HI, Sadock VA. Kaplan & Sadock’s Synopsis of Psy-
chiatry: Behavioral Sciences/ Clinical Psychiatry. Philadelphia: Lippin-
cott Williams & Wilkins; 2007.
5. Guberman AH, Besag FM, Brodie MJ, Dooley JM, Duchowny MS, Pel-
lock JM, et al. Lamotrigine-associated rash: risk/benefit considerations 
in adults and children. Epilepsia 1999;40:985-991.
6. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of 
Stevens-Johnson syndrome and toxic epidermal necrolysis in new users 
of antiepileptics. Neurology 2005;64:1134-1138.
7. Leeder JS. Mechanisms of idiosyncratic hypersensitivity reactions to 
antiepileptic drugs. Epilepsia 1998;39(Suppl 7):S8-S16.
8. Roujeau JC. Immune mechanisms in drug allergy. Allergol Int 2006;55: 
27-33.
9. Rapp RP, Norton JA, Young B, Tibbs PA. Cutaneous reactions in head-
injured patients receiving phenytoin for seizure prophylaxis. Neurosur-
gery 1983;13:272-275.
10. Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, ran-
domised comparison between lamotrigine and carbamazepine in el-
derly patients with newly diagnosed epilepsy. The UK Lamotrigine El-
derly Study Group. Epilepsy Res 1999;37:81-87.
11. Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in 
newly diagnosed epilepsy: a multicentre randomised double-blind 
study. Vigabatrin European Monotherapy Study Group. Lancet 1999; 
354:13-19.
12. Wong IC, Mawer GE, Sander JW. Factors influencing the incidence of 
lamotrigine-related skin rash. Ann Pharmacother 1999;33:1037-1042.
13. Hirsch LJ, Weintraub DB, Buchsbaum R, Spencer HT, Straka T, Hager 
M, et al. Predictors of Lamotrigine-associated rash. Epilepsia 2006; 
47:318-322.
14. Chou JC, Fazzio L. Maintenance treatment of bipolar disorder: Apply-
ing research to clinical practice. J Psychiatr Pract 2006;12:283-299.
15. Caranasos GJ, Stewart RB, Cluff LE. Drug-induced illness leading to 
hospitalization. JAMA 1974;228:713-717.
16. Messenheimer JA. Rash in adult and pediatric patients treated with la-
motrigine. Can J Neurol Sci 1998;25:S14-S18.
17. Schatzberg AF. Employing pharmacologic treatment of bipolar disorder 
to greatest effect. J Clin Psychiatry 2004;65(Suppl 15):15-20.
18. Kowatch RA, DelBello MP. Pharmacotherapy of children and adoles-
cents with bipolar disorder. Psychiatr Clin North Am 2005;28:385-397.
19. Bhangoo RK, Lowe CH, Myers FS, Treland J, Curran J, Towbin KE, et 
al. Medication use in children and adolescents treated in the communi-
ty for bipolar disorder. J Child Adolesc Psychopharmacol 2003;13:515-
522.
20. Chang K, Saxena K, Howe M. An open-label study of lamotrigine ad-
junct or monotherapy for the treatment of adolescents with bipolar de-
pression. J Am Acad Child Adolesc Psychiatry 2006;45:298-304.
21. Biederman J, Joshi G, Mick E, Doyle R, Georgiopoulos A, Hammerness 
P, et al. A prospective open-label trial of lamotrigine monotherapy in 
children and adolescents with bipolar disorder. CNS Neurosci Ther 
2010;16:91-102.
22. Chang JS, Joe SH, Cha BS, Moon ES, Ha TH, Yoon IY, et al. Lamotrigi-
ne augmentation in patients with treatment-resistant major depressive 
disorder: a naturalistic study. Korean J Psychopharmacol 2008;19:276-
282.
23. Woo YS, Bahk WM, Jon DI, Joo YH, Kim W, Seo JS, et al. Rash in adult 
patients receiving lamotrigine to treat bipolar I disorder in Korea: a 
multicenter, prospective, naturalistic, open-label trial. Prog Neuropsy-
chopharmacol Biol Psychiatry 2009;33:1147-1152.
24. Zeng K, Wang X, Xi Z, Yan Y. Adverse effects of carbamazepine, phe-
nytoin, valproate and lamotrigine monotherapy in epileptic adult Chi-
nese patients. Clin Neurol Neurosurg 2010;112:291-295.
25. Alvestad S, Lydersen S, Brodtkorb E. Rash from antiepileptic drugs: in-
fluence by gender, age, and learning disability. Epilepsia 2007;48:1360-
1365.
26. Tran C, Knowles SR, Liu BA, Shear NH. Gender differences in adverse 
drug reactions. J Clin Pharmacol 1998;38:1003-1009.
27. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis 
and Practical Applications, 3rd Edition. Cambridge: Cambridge Univer-
sity Press; 2008.
28. Choonara I, Gill A, Nunn A. Drug toxicity and surveillance in children. 
Br J Clin Pharmacol 1996;42:407-410.
29. Rodnitzky RL. Drug-induced movement disorders in children and ad-
olescents. Expert Opin Drug Saf 2005;4:91-102.
30. Aguilar EJ, Keshavan MS, Martinez-Quiles MD, Hernandez J, Gomez-
Beneyto M, Schooler NR. Predictors of acute dystonia in first-episode 
psychotic patients. Am J Psychiatry 1994;151:1819-1821.